clinical trial · NCT06680531
A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.·phase1·active not recruiting·n = 24
InsomniaCentral Nervous SystemYZJ-1139 tabletsEscitalopram oxalate tabletsYZJ-1139 simulated tablets
brief summary
Primary Objective: 1\) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.
started
Aug 31, 2024
primary completion
Sep 18, 2024
completion
Jan 1, 2025
last updated
Nov 8, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol